Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
出版年份 2016 全文链接
标题
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 19, Issue 1, Pages 3-12
出版商
Wiley
发表日期
2016-09-05
DOI
10.1111/dom.12782
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection
- (2015) Paola Lucidi et al. DIABETES CARE
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
- (2015) R. Ritzel et al. DIABETES OBESITY & METABOLISM
- Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
- (2015) Sarah L. Greig et al. DRUGS
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- (2015) Tim Heise et al. Expert Opinion on Drug Metabolism & Toxicology
- Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
- (2015) Svend Havelund et al. PHARMACEUTICAL RESEARCH
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
- (2014) Robert R. Henry et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
- (2014) Jiten Vora et al. Diabetes Therapy
- A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec
- (2013) Stefan Korsatko et al. CLINICAL DRUG INVESTIGATION
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes
- (2013) Stephen C.L. Gough et al. DIABETES CARE
- PEGylated insulin Lispro, (LY2605541)-a new basal insulin analogue
- (2013) T. M. Caparrotta et al. DIABETES OBESITY & METABOLISM
- Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
- (2013) V. P. Sinha et al. DIABETES OBESITY & METABOLISM
- Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
- (2013) Tim Heise et al. Endocrine Practice
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec
- (2012) Dorte B. Steensgaard et al. BIOCHEMISTRY
- Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy Tested in a Randomized Trial in Type 1 Diabetic Patients
- (2012) J. K. Mader et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
- (2011) A. de la Pena et al. DIABETES CARE
- Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes
- (2011) S. Zachariah et al. DIABETES CARE
- Bioavailability and variability of biphasic insulin mixtures
- (2011) Tue Søeborg et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
- (2010) S. G. Swinnen et al. DIABETES CARE
- Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
- (2010) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial
- (2009) Simon Heller et al. CLINICAL THERAPEUTICS
- Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
- (2009) Philip Raskin et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
- (2008) Priscilla Hollander et al. CLINICAL THERAPEUTICS
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETOLOGIA
- Absorption kinetics of insulin after subcutaneous administration
- (2008) Tue Søeborg et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More